959237-64-0

Usage

Uses

Used in Pharmaceutical Industry:
2,4-DICHLORO-8-FLUORO-QUINAZOLINE is used as a building block for the synthesis of pharmaceuticals, due to its potential to act as an intermediate in the production of these substances. Its unique structure and reactivity contribute to the development of various compounds with therapeutic applications.
Used in Agrochemical Industry:
2,4-DICHLORO-8-FLUORO-QUINAZOLINE is used as a building block for the synthesis of agrochemicals, serving as an intermediate in the production of these substances. Its chemical properties make it suitable for the development of compounds with applications in agriculture, such as pesticides and herbicides.
Used in Research and Development:
2,4-Dichloro-8-fluoro-quinazoline is used in research and development for the exploration of new materials and chemical processes. Its unique structure and reactivity provide opportunities for the discovery of novel compounds and applications in various fields.

InChI:InChI=1/C8H3Cl2FN2/c9-7-4-2-1-3-5(11)6(4)12-8(10)13-7/h1-3H

Upstream product

• 590-28-3 potassium cyanate 
• 825-22-9 3-fluoroanthranilic acid 
• 959236-96-5 8-fluoroquinazoline-2,4(1H,3H)-dione 

Downstream Products

• 139996-64-8 2-chloro-8-fluoro-N-methyl-N-phenylquinazolin-4-amine 
• 1292802-72-2 2-N-(3-(4-(2,3-dichlorophenyl)piperazin-1-yl)propyl)-8-fluoro-4-N-(furan-2-ylmethyl)quinazoline-2,4-diamine 

Relevant academic research and scientific papers

Synthesis and biological evaluation of 2,4-diaminoquinazoline derivatives as novel heat shock protein 90 inhibitors

Novel 2,4-diaminoquinazoline derivatives originating from a virtual screening approach were designed, synthesized and their biological activities as heat shock protein 90 (Hsp90) inhibitors were evaluated. The prepared compounds exhibited significant anti-proliferative activities against DU-145, HT-29, HCT-116, A375P and MCF-7 cancer cell lines. The selected compounds were tested against Her2, a client protein of Hsp90, and showed significant reduction in Her2 protein expression. Compound 6b was found the most potent, reduced Her2 protein expression levels and induced Hsp70 protein expression levels significantly.

ADENOSINE A2A RECEPTOR ANTAGONISTS

Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein: X1 and X2 are 1-3 substituents independently selected from the group consisting of H, alkyl, halo, —CF3, —OCF3, alkoxy, —OH and —CN;n is 0, 1 or 2; andR and R1 are H or alkyl; also disclosed is the use of the compounds in the treatment of CNS diseases such as Parkinson's disease, alone or in combination with other agents for treating CNS diseases, pharmaceutical compositions comprising them and kits comprising the components of the combinations.

Reversible Inhibitors of the Gastric (H+/K+)-ATPase. 5. Substituted 2,4-Diaminoquinazolines and Thienopyrimidines

Quinazolines bearing a secondary 4-(arylamino) substituent demonstrate an SAR for inhibition of the gastric (H+/K+)-ATPase different from the previously described 3-acylquinolines, suggesting that, although these compounds are also K+-competitive, they probably bind to the enzyme in a different orientation.Compounds bearing a tertiary 4-(arylamino)substituent, however, in particular 4-(N-methylarylamino), appear to possess an SAR quite similar to the 3-acylquinolines.We show that this arises from the effect of the N-methylation, which is to orientate the 4-(arylamino) substituent syn to C5, analogous to the 3-acylquinolines.Compounds possessing both a 4-(N-methylarylamino) substituent and a 2-(arylamino) substituent proved to be very potent, K+-competitive inhibitors of K+-stimulated ATPase activity with Ki values down to 12 nM.Some compounds also proved to be effective inhibitors of stimulated acid secretion in both the rat and dog when dosed intravenously.However, although a number of these demonstrated activity after oral administration in the dog, the level and variability precluded further evaluation.